Cryoablation for Advanced and Refractory Desmoid Tumors (CARDT)

University Hospital, Strasbourg, France

Status: Enrolling

Conditions: Desmoid Tumors

Study type: Observational

Funder types: Other

Identifiers

NCT06113094

7884

Details and patient eligibility

About

Desmoid tumors, also called aggressive fibromatosis, are rare, locally invasive tumors with no potential for metastasis. The incidence is approximately 2 to 4 per million per year in the general population. The "watch and wait" policy is the standard of care for newly diagnosed patients in Europe. Patients who progress have first-line medical treatment, surgery is no longer the treatment because there is a high rate of recurrence (> 60%) and radiotherapy is not very suitable because the patients are often young and the tumors are large. Cryoablation seems to be an effective therapeutic option that should be evaluated.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patient (≥18 years old)
• Having undergone cryoablation for an advanced desmoid tumor refractory to medical treatment
• Having not expressed their opposition, after being informed, to the reuse of their data for the purposes of this research.

Exclusion criteria

• Subject who expressed their opposition to participating in the study
• Patient already included in another ongoing study
• Subject under guardianship or curatorship
• Subject under safeguard of justice